Comparing Apollo Endosurgery (APEN) & Entellus Medical (ENTL)

Apollo Endosurgery (NASDAQ: APEN) and Entellus Medical (NASDAQ:ENTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Risk & Volatility

Apollo Endosurgery has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Entellus Medical has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.

Earnings and Valuation

This table compares Apollo Endosurgery and Entellus Medical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Apollo Endosurgery $63.01 million 1.44 -$10.53 million N/A N/A
Entellus Medical $80.80 million 6.18 -$26.99 million ($1.66) -11.85

Apollo Endosurgery has higher revenue, but lower earnings than Entellus Medical.

Institutional and Insider Ownership

8.9% of Apollo Endosurgery shares are held by institutional investors. Comparatively, 70.3% of Entellus Medical shares are held by institutional investors. 74.2% of Apollo Endosurgery shares are held by insiders. Comparatively, 7.7% of Entellus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Apollo Endosurgery and Entellus Medical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollo Endosurgery 0 0 3 0 3.00
Entellus Medical 1 2 4 0 2.43

Apollo Endosurgery presently has a consensus target price of $11.00, indicating a potential upside of 108.73%. Entellus Medical has a consensus target price of $21.83, indicating a potential upside of 11.00%. Given Apollo Endosurgery’s stronger consensus rating and higher possible upside, analysts plainly believe Apollo Endosurgery is more favorable than Entellus Medical.

Profitability

This table compares Apollo Endosurgery and Entellus Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apollo Endosurgery -81.59% -142.98% -54.80%
Entellus Medical -41.11% -60.34% -36.76%

Summary

Entellus Medical beats Apollo Endosurgery on 7 of the 12 factors compared between the two stocks.

About Apollo Endosurgery

Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.

About Entellus Medical

Entellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company’s XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.

Receive News & Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply